DDX3-IN-2

Research use only, not for human use.

DDX3-IN-2, a potent inhibitor of DEADbox polypeptide 3 (DDX3), demonstrates remarkable activity against the target with an IC50 value of 0.3 μM.

DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance.

DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase.

DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg.DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values.Animal Model:Wistar rats Dosage:Tail vein injection Administration:20 mg/kg Result:Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.Animal Model:Rats Dosage:I.v. bolus injection (Pharmacokinetic Analysis) Administration:10 mg/kg; 0~25 hours Result:Rapidly eliminated the half-life elimination and the plasmatic clearance values.

——

Others

Other Targets

Others

——

——

1919828-81-1

349.43

C20H23N5O

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (286.18 mM; Ultrasonic )

CCCCc1cn(nn1)-c1ccc(NC(=O)Nc2ccccc2C)cc1

——

(-20℃)

With Ice Pack

≥ 2 years